-
1.发明公开
公开(公告)号：EP3572409A1
公开(公告)日：2019-11-27
申请号：EP18742199.5
申请日：2018-01-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： HUANG, Ticong , XIAO, Huifeng , ZHAO, Rui , LIU, fei , WEI, Wei , XU, Hongjiang , WANG, Xiaojin , WU, Jingli
IPC分类号： C07D401/14 , A61K31/5377 , A61P35/00
摘要： The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl) -N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
-
公开(公告)号：EP3176160A1
公开(公告)日：2017-06-07
申请号：EP15826817.7
申请日：2015-07-31
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号： C07D401/14 , C07D213/73 , A61K31/496 , A61K31/444 , A61P35/00
CPC分类号： C07D401/14 , A61K31/444 , A61K31/496 , C07D213/73
摘要： The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.
摘要翻译： 本发明公开了作为蛋白激酶抑制剂的吡啶取代的2-氨基吡啶衍生物的药学上可接受的酸式盐，其制备方法，药物组合物及其用于治疗与蛋白激酶相关的疾病的用途。
-
公开(公告)号：EP3444237B1
公开(公告)日：2020-10-28
申请号：EP17769433.8
申请日：2017-03-22
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , YANG, Yanqing , DAI, Liguang , DUAN, Xiaowei , YANG, Zhao , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D203/24 , A61K31/396 , A61P35/00
-
公开(公告)号：EP3330264B1
公开(公告)日：2020-05-06
申请号：EP16829879.2
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号： C07D401/14 , A61K31/496 , A61P35/00
-
公开(公告)号：EP3434671A1
公开(公告)日：2019-01-30
申请号：EP17769434.6
申请日：2017-03-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , DUAN, Xiaowei , DAI, Liguang , YANG, Zhao , YANG, Yanqing , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D275/02 , A61K31/425 , A61K31/433 , A61P35/00
摘要： Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
-
公开(公告)号：EP3330264A1
公开(公告)日：2018-06-06
申请号：EP16829879.2
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号： C07D401/14 , A61K31/496 , A61P35/00
摘要： The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin -1-yl)-3,3'-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin-1-yl)-3,3'-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin-1-yl)-3,3'-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.
-
公开(公告)号：EP3434671B1
公开(公告)日：2020-10-21
申请号：EP17769434.6
申请日：2017-03-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , DUAN, Xiaowei , DAI, Liguang , YANG, Zhao , YANG, Yanqing , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： A61K31/425 , A61K31/433 , A61P35/00 , C07D275/03 , C07D285/10 , A61P35/02
-
公开(公告)号：EP3444237A1
公开(公告)日：2019-02-20
申请号：EP17769433.8
申请日：2017-03-22
申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , YANG, Yanqing , DAI, Liguang , DUAN, Xiaowei , YANG, Zhao , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D203/24 , A61K31/396 , A61P35/00
摘要： An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation- induced cancer.
-
9.发明公开
公开(公告)号：EP4279138A3
公开(公告)日：2024-03-27
申请号：EP23198543.3
申请日：2019-03-01
发明人： GONG, Feng , HUANG, Ticong , ZANG, Haishan , ZHANG, Shibo , ZHAO, Rui , LIU, Fei
IPC分类号： C07D215/22 , A61K31/47 , A61P35/00
摘要： The present application falls within the field of medicinal chemistry, relates to the crystal of a compound as a c-Met kinase inhibitor, and specifically relates to the crystal of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fl uorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystal for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystal of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.
-
10.发明公开
公开(公告)号：EP3816161A1
公开(公告)日：2021-05-05
申请号：EP19826745.2
申请日：2019-06-24
发明人： DONG, Ping , HE, Xiongxiong , LIU, Lei , ZHAO, Rui
IPC分类号： C07D401/12 , A61K31/4709 , A61P35/00 , A61K9/14
摘要： The present application relates to the field of pharmaceutical technology, specifically to the crystal habit and crystalline powder preparation of quinoline derivatives, and more specifically, to the crystal habit and crystalline powder preparation of anlotinib dihydrochloride. The compound of formula II disclosed herein is a crystalline powder with a flaky crystal habit having a specific surface area ≥ 10 m 2 /g and a particle-size distribution of X 50 ≤ 50 µm and/or X 90 ≤ 500 µm, such that a large specific surface area is provided without reducing the particle size of the drug by a physical method under the condition of a broad particle-size distribution, and the drug can rapidly dissolving. In addition to excellent dissolution property, the crystalline powder is also beneficial to industrial manufacturing, featuring simplified process and cost-efficiency.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.022 秒)
